Pay in 4 interest-free payments of $375.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
The intensity of the color is positively correlated with the amount of S100 Calcium Binding Protein A5 (S100A5) in the sample
B- and T-lymphocyte-associated protein
apoptotic cells can be observed by flow cytometry by measuring changes in light scattering
SHP-2 is also associated with a variety of diseases
the ALOX15 protein also has important applications in the medical field
ActRIIA Enzyme Activity Inhibitor Screening Kit Isotype control The intensity of the colorProduct Specification Species Human Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibition of the ACTRII signaling pathway has been shown to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving
US$ 148.00
US$ 187.50
US$ 240.00
US$ 187.50
US$ 120.00
US$ 2830.00
US$ 3920.00
US$ 4280.00
US$ 10770.00
US$ 3410.00
US$ 3630.00
US$ 180.00
US$ 32.00
US$ 90.00
US$ 3690.00
US$ 57.50